Purpose: The objective of this study was to investigate nationwide survival outcomes in men with localized prostate cancer managed on active surveillance. 
CURATIVE options for localized prostate cancer are available, although the effect on survival in men with more favorable risk features is limited.
1e5 Still, some men with favorable risk prostate cancer die of the disease. 1 Active surveillance has been introduced as a tailored treatment in select men with localized prostate cancer to reduce overtreatment by identifying those who will likely benefit from definitive therapy, while men with true favorable risk prostate cancer are spared curative interventions and its adverse effects. 2, 3 Large, prospective active surveillance cohorts with predefined followup programs and criteria for recommending curative therapy have achieved excellent 98% to 99% 10-year cause specific survival. 6e9 Followup in these cohorts include regular PSA testing, digital rectal Accepted for publication September 7, 2018 . The corresponding author certifies that, when applicable, a statement(s) has been included in the manuscript documenting institutional review board, ethics committee or ethical review board study approval; principles of Helsinki Declaration were followed in lieu of formal ethics committee approval; institutional animal care and use committee approval; all human subjects provided written informed consent with guarantees of confidentiality; IRB approved protocol number; animal approved project number.
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No direct or indirect commercial, personal, academic, political, religious or ethical incentive is associated with publishing this article. examinations and sequential surveillance biopsies. The ProtecT study, the first randomized, controlled trial comparing curative interventions (ie radical prostatectomy and radiotherapy) to an active monitoring strategy, revealed no survival difference between the treatment strategies. 10 In that study men on active monitoring underwent regular PSA testing and a change to curative treatment was primarily based on PSA. Ten-year cause specific survival in men on active monitoring was 98.8%.
To our knowledge the safety of men with localized prostate cancer managed on active surveillance outside prospective cohorts is unknown. Well performed observational studies can elucidate the effectiveness of management in a real world setting and they are important additions to clinical trials for clinical decision making. 11, 12 The objective of this study was to investigate results in men with localized prostate cancer managed on active surveillance in Denmark. We identified men who initiated active surveillance in 2002 to 2012. This enabled us to define a MRI na€ ıve cohort. MRI was not part of the diagnostic evaluation and for the majority, surveillance MRI was not available for the initial years of surveillance when most men who undergo subsequent curative treatment will change strategy. 13 
MATERIAL AND METHODS
Patients diagnosed with prostate cancer initially on active surveillance between January 1, 2002 and December 31, 2012 were identified at 10 Danish urological departments (Aalborg, Esbjerg, Frederiksberg, Herlev, Naestved, Odense, Rigshospitalet, Roskilde, Skejby and Viborg). Patient chart review was performed at Aalborg, Esbjerg, Frederiksberg, Naestved, Roskilde, Skejby and Viborg for men who underwent 2 or more prostate biopsies, while local registration of men on active surveillance was performed at Herlev, Odense and Rigshospitalet. The data retrieved at the time of initiating active surveillance included year, patient age, cT category, diagnostic Gleason score recorded according to the 5-tier GGG, 14 PSA in ng/ml, TRUS estimated prostate volume, number of biopsies, number of positive core biopsies and maximum tumor involvement in any 1 core. The number of surveillance biopsies was also documented.
Baseline PSA was defined in men diagnosed with biopsy as the last PSA before the diagnostic biopsy. In men diagnosed following transurethral resection of the prostate the PSA nadir after the procedure was used. In men diagnosed following a biopsy PSA density was calculated in ng/ml/cc as PSA divided by TRUS estimated prostate volume.
Prostate cancer was grouped into 4 risk categories according to a modified NCCNÒ (National Comprehensive Cancer NetworkÒ) risk categorization, including 1) very low riskdcT1, GGG 1, PSA less than 10 ng/ml, PSA density less than 0.15 ng/ml/cc, 1 or 2 positive biopsy cores and 50% or less cancer in any 1 core; 2) low riskdcT1-2a, GGG 1 and PSA less than 10 ng/ml; 3) intermediate riskdcT2b-2c and/or GGG 2-3 and/or PSA 10 to 20 ng/ml; and 4) high riskdPSA greater than 20 (no patient had cT3 or Descriptive statistics are used to describe baseline characteristics. Followup was calculated with the reverse Kaplan-Meier method. Survival probabilities were assessed on Kaplan-Meier analyses and are presented with the 95% CI. The log rank test was used to assess differences between subgroups. The association between baseline characteristics and subsequent treatments was assessed by Cox proportional hazard regression analyses including the categorical variables year of commencing active surveillance, age, cT, PSA, PSA density, GGG, number of positive biopsy cores and maximum percent tumor in any 1 core. Missing values were included as an individual group. Results are presented as the HR with the 95% CI. Statistical analysis was performed with R (https://www.r-project.org/foundation/). All tests were 2-sided and significance was considered at p <0.05.
RESULTS
We identified 936 men diagnosed with prostate cancer and initially followed on active surveillance (table 1) . Median followup was 7.5 years (IQR 6.1e9.1), 840 men (90%) underwent at least 1 surveillance biopsy and the median number of surveillance biopsies was 2 (IQR 1e2). Of the men 24% and 47% had very low and low risk prostate cancer, respectively, while 28% had intermediate risk prostate cancer, including 33 with unfavorable intermediate risk prostate cancer, and 2% had high risk prostate cancer because of PSA above 20 ng/ml.
During followup 320 men underwent curative treatment. A total of 250 men underwent radical prostatectomy, 53 underwent external beam radiotherapy, 15 underwent brachytherapy and 2 underwent radical cystoprostatectomy because of subsequent bladder cancer. Five-year curative treatment-free survival was 69.1% (95% CI 66.0e71.9) and 10-year curative treatment-free survival was 62.8% (95% CI 59.1e66.3, fig. 1, A) .
Men diagnosed in 2010 to 2012 and men 70 years old or older at diagnosis were less likely to undergo curative treatment, while PSA density higher than 0.1 ng/ml/cc was associated with an increased risk of undergoing curative treatment ( During followup 91 men died, including 3 of prostate cancer, corresponding to 10-year overall survival of 87.2% (95% CI 84.0e89.9) and 10-year cause specific survival of 99.6% (95% CI 98.6e99.9, fig. 1, B) . There was no difference among risk groups (table 3) . Two of the 3 men who died of prostate cancer were classified with low risk prostate cancer, while the remaining man had intermediate risk prostate cancer. Two of the 3 men underwent radical prostatectomy within 1 year of initiating surveillance and both experienced early biochemical recurrence and commenced hormonal therapy. The final man with low risk prostate cancer was diagnosed with distant metastases following 3 years of surveillance and commenced hormonal therapy. Imaging in this man was performed during workup following a surveillance biopsy, which revealed an upgrade to GGG 4.
During followup hormonal therapy commenced in 50 men (5%), ie antiandrogen monotherapy in 27 and castration therapy in 23, corresponding to 10-year hormonal therapy-free survival of 92.2% (95% CI 89.2e94.4, table 3). No difference was observed between men who did and did not undergo curative treatment ( fig. 2, A) . Men 70 years old or older, men with PSA higher than 5 ng/ml and men with missing PSA density, including the 64 diagnosed following transurethral prostate resection, were at higher risk for commencing hormonal therapy ( 
DISCUSSION
In this nationwide observational study in men with localized prostate cancer managed on active 
* Very low riskdcT1, GGG 1, PSA less than 10 ng/ml, PSA density less than 0.15 ng/ml/cc, 1 or 2 positive biopsy cores and maximum 50% cancer in any core; low riskdcT1-2a, GGG 1 and PSA less than 10 ng/ml; intermediate riskdcT2b-c and/or GGG 2-3 and/or PSA 10 to 20 ng/ml; and high riskdPSA greater than 20 ng/ml.
surveillance in Denmark we found 10-year cause specific survival similar to that of prospective active surveillance cohorts. The main limitation of the retrospective design is potential incomplete capture as there was no national database in the study period with data on which men were on active surveillance. Moreover, 11 Danish urological departments were primary referral centers in the study period but 1 department chose not to participate. Although this department refers men diagnosed with prostate cancer who are candidates for curative treatment to a tertiary referral center, it is possible that men diagnosed at this department were not included in study.
Another limitation of the design is that there was no uniform surveillance strategy at the different departments. However, at all centers men were assessed with a combination of surveillance biopsies, regular PSA measurements and digital rectal examinations. On the other hand, a thorough patient chart review was performed for all identified men with almost complete baseline data and there was complete followup, including all cancer therapies performed and survival status.
The short-term, 5-year curative treatment-free survival of 69.1% is higher than the 50% to 64% observed in the prospective cohorts. 6e9 This could indicate that the men in the current study were treated with less intensive surveillance, ie fewer surveillance biopsies, with a subsequent lower risk of biopsy reclassification. Another possibility is that there was a more frequent change from active surveillance to watchful waiting, ie a strategy in which curative treatment is no longer considered an option and men are only followed with PSA and digital rectal examination to initiate subsequent hormonal therapy when required. This in particular seems the case for men 70 years old or older, who were less likely to undergo curative treatment but more likely to commence hormonal therapy. Surprisingly and somewhat counterintuitively, we observed higher curative treatment-free survival in men with intermediate risk prostate cancer than in men with low risk prostate cancer. It is likely that men with intermediate risk prostate cancer were reluctant to undergo curative treatment at diagnosis and progression on surveillance biopsies leading to recommending curative treatment is less likely in men with GGG 2 than GGG 1 disease.
The current study represents an active surveillance cohort of men in which a relatively large proportion had intermediate risk or high risk prostate cancer compared to published prospective cohorts (30% vs 0% to 25%).
6e9 Still, with 99.6% 10-year cause specific survival we confirm that active surveillance in a real world setting can produce survival results similar to the 98% to 99% in prospective active surveillance cohorts 6, 7 and the 98.8% in the active monitoring arm of the ProtecT study. 10 However, there are still concerns about the longterm safety of this strategy. The prospective € Orebro, Sweden cohort study and a Danish registry based study demonstrated that cause specific mortality is not insignificant in men on watchful waiting who survive 10 years or more. 16, 17 Importantly, in these studies curative treatments were not available and the Sunnybrook active surveillance cohort demonstrated 15-year cause specific mortality which was half that observed in the comparable subgroup in the € Orebro cohort (5.7% vs 11%). 6 Moreover, a previous report from the Sunnybrook cohort questioned the safety of active surveillance in men with intermediate risk prostate cancer. 18 However, that study included only men with intermediate risk prostate cancer diagnosed before 2000. The current study * Very low riskdcT1, GGG 1, PSA less than 10 ng/ml, PSA density less than 0.15 ng/ml/cc, 1 or 2 positive biopsy cores and maximum 50% cancer in any core; low riskdcT1-2a, GGG 1 and PSA less than 10 ng/ml; intermediate riskdcT2b-c and/or GGG 2-3 and/or PSA 10 to 20 ng/ml; and high riskdPSA greater than 20 ng/ml. The practice in Denmark is to initiate castration therapy if imaging detects metastatic disease. Antiandrogen monotherapy is initiated in men on surveillance who are no longer candidates for curative treatment without the presence of metastases if extraprostatic extension is suspected on digital rectal examination, the PSA level rises rapidly and/or reaches a level above 50 ng/ml or following curative treatment if distant failure is suspected. Thus, we were not able to assess metastasis-free survival. We observed no difference in the surrogate end points of hormonal therapyfree and castration resistant prostate cancer-free survival between men who did and did not undergo curative treatment. This indicates that only a few men who could have benefitted from curative treatment did not undergo such interventions. Although these results are promising, men on active monitoring in the ProtecT study were at higher risk for clinical progression, including progression to metastatic disease, than men who underwent curative interventions. 10 Thus, more studies comparing active surveillance to curative treatment modalities are still warranted.
Although active surveillance is an accepted treatment strategy and it is recommended in guidelines to men with very low or low risk prostate cancer, 2,3 the strategy is evolving. About a third of the men with low risk prostate cancer who undergo immediate radical prostatectomy harbor GGG 2 or higher and more than 10% present with extraprostatic extension in the prostatectomy specimen. 22 On the other hand, up to 50% of men with progression on active surveillance who undergo radical prostatectomy had true low risk disease at surgery, ie pT2 and GGG 1. 22 Efforts are being made to increase the precision in which curative treatments are recommended. 23e25 Currently multiparametric MRI is the only marker that has been recommend in the EAU guidelines and introduced in the treatment of men on active surveillance on a large scale. 3, 6, 24 This modality seems to detect potentially lethal tumors missed by TRUS guided biopsy. 26 However, this could also lead to new overtreatment issues as we still do not fully understand how to clinically interpret the pathology of a MRI targeted biopsy. Moreover, it seems unlikely that an active surveillance program including MRI could achieve better outcomes in terms of cancer specific survival. On the other hand, in the future MRI may enable us to broaden the selection criteria for active surveillance, reduce the number of surveillance biopsies and decrease the number of men who need to undergo curative treatments.
CONCLUSIONS
In this nationwide observational study of men with localized prostate cancer on active surveillance in Denmark we found cause specific survival similar to that of prospective active surveillance cohorts in the intermediate time frame. Men with intermediate risk prostate cancer were less likely to undergo curative treatment but had similar castration resistant, treatment-free survival compared to men with low risk prostate cancer. Our study supports active surveillance as a treatment strategy in men with localized prostate cancer, including men with intermediate risk characteristics.
